Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein light chain 1, cytoplasmic (DYNLL1)
- Target
- DYNLL1
- Molecular classification
- Cytoskeletal motor protein subunit, Accessory/adaptor protein, Protein-protein interaction module, Other (Specifically a component of the cytoplasmic dynein motor complex)
01
Overview
Dynein light chain 1, cytoplasmic (DYNLL1) is a non-catalytic accessory subunit of the cytoplasmic dynein 1 motor complex, which facilitates microtubule-based intracellular transport of vesicles and organelles. Besides its role in cargo binding and cytoskeletal structure regulation, DYNLL1 acts as a protein interaction adaptor, sequestering or inhibiting proteins such as neuronal nitric oxide synthase and BCL2L11, thereby modulating nitric oxide signaling, apoptosis, DNA double-strand break repair, and transcriptional regulation via interaction with ESR1. Although not currently drug-targeted, its key cellular roles make it a subject of interest in neurodevelopmental disorders, ciliopathies, cancer biology, and signal transduction research.
- Other names
- DYL1DLC1DNCL1DNCLC1HDLC1DLC8PINLC88 kDa dynein light chainProtein inhibitor of neuronal nitric oxide synthaseLC8a
02
Mechanism of action
not established. No drugs directly targeting DYNLL1; however, its functional mechanisms include: - Protein-protein interaction inhibition/sequestration (e.g., neuronal nitric oxide synthase inhibition) - Modulation of DNA repair and apoptosis through interactions with BCL2L11 and TP53BP1
03
Biological functions
Intracellular transport and motility (microtubule-based)Cytoskeletal organizationProtein-protein adaptorRegulates neuronal nitric oxide synthase activityDNA damage response/modulates DNA end resectionApoptosis regulationTranscriptional regulation (modulates ESR1 function and localization)
04
Disease associations
Neurodevelopmental disorders (e.g., lissencephaly 1)Ciliopathies (e.g., Bardet-Biedl syndrome)Cancer (regulation of apoptosis and DNA damage response)Other (Functional link to neurodegenerative disease and signaling defects are possible but less established)
05
Safety considerations
none established for direct drug targeting; however, inhibition or dysregulation could potentially disrupt essential intracellular transport, cell signaling, DNA damage response, and apoptosis and may cause off-target effects affecting multiple cellular pathways or lead to neurodevelopmental or apoptotic dysregulation
06
Interacting drugs
none reported as direct clinical drugs
07
Biomarkers
none established for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Dynein light chain 1, cytoplasmic (DYNLL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dynein light chain 1, cytoplasmic (DYNLL1).